171 related articles for article (PubMed ID: 34549721)
1. [Effects of neoadjuvant chemoradiotherapy on infiltrating immune cells in the tumor microenvironment of rectal cancer].
Yang Q; Zhou C; Han C; Zhang Y; Jiang Y; Li Z; Ma J
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(8):1270-1276. PubMed ID: 34549721
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
[TBL] [Abstract][Full Text] [Related]
3. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy.
Miyakita H; Sadahiro S; Suzuki T; Chan LF; Ogimi T; Okada K; Yamamoto S; Kajiwara H
Oncology; 2020; 98(12):869-875. PubMed ID: 32799200
[TBL] [Abstract][Full Text] [Related]
5. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Infiltrating PD-1+ Immune Cell Density is Associated with Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.
Kitagawa Y; Akiyoshi T; Yamamoto N; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Fukunaga Y; Hirota T; Noda T; Kawachi H
Clin Colorectal Cancer; 2022 Mar; 21(1):e1-e11. PubMed ID: 35123891
[TBL] [Abstract][Full Text] [Related]
7. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.
Imaizumi K; Suzuki T; Kojima M; Shimomura M; Sakuyama N; Tsukada Y; Sasaki T; Nishizawa Y; Taketomi A; Ito M; Nakatsura T
Cancer Sci; 2020 Jan; 111(1):23-35. PubMed ID: 31660687
[TBL] [Abstract][Full Text] [Related]
8. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response.
McCoy MJ; Hemmings C; Anyaegbu CC; Austin SJ; Lee-Pullen TF; Miller TJ; Bulsara MK; Zeps N; Nowak AK; Lake RA; Platell CF
Oncotarget; 2017 Mar; 8(12):19803-19813. PubMed ID: 28177891
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
Schollbach J; Kircher S; Wiegering A; Seyfried F; Klein I; Rosenwald A; Germer CT; Löb S
Cancer Immunol Immunother; 2019 Apr; 68(4):563-575. PubMed ID: 30671614
[TBL] [Abstract][Full Text] [Related]
10. 53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer.
Huang A; Xiao Y; Peng C; Liu T; Lin Z; Yang Q; Zhang T; Liu J; Ma H
Strahlenther Onkol; 2020 May; 196(5):465-473. PubMed ID: 31828392
[TBL] [Abstract][Full Text] [Related]
11. Effect of neoadjuvant chemoradiation on tumor-infiltrating/associated lymphocytes in locally advanced rectal cancers.
Lim SH; Chua W; Cheng C; Descallar J; Ng W; Solomon M; Bokey L; Wong K; Lee MT; de Souza P; Shin JS; Lee CS
Anticancer Res; 2014 Nov; 34(11):6505-13. PubMed ID: 25368252
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral Budding and CD8-Positive T-cell Density in Pretreatment Biopsies as a Predictor of Response to Neoadjuvant Chemoradiotherapy in Advanced Rectal Cancer.
Sano S; Akiyoshi T; Yamamoto N; Hiyoshi Y; Mukai T; Yamaguchi T; Nagasaki T; Taketomi A; Fukunaga Y; Kawachi H
Clin Colorectal Cancer; 2023 Dec; 22(4):411-420.e1. PubMed ID: 37516615
[TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment Mediators CD8
Zaghloul H; Abbas A; Abdulah D
J Gastrointest Cancer; 2021 Mar; 52(1):177-186. PubMed ID: 32112202
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
15. Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.
Sawada R; Akiyoshi T; Kitagawa Y; Hiyoshi Y; Mukai T; Nagasaki T; Yamaguchi T; Konishi T; Yamamoto N; Ueno M; Fukunaga Y
Ann Surg Oncol; 2021 Oct; 28(11):6189-6198. PubMed ID: 33876358
[TBL] [Abstract][Full Text] [Related]
16. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer.
Matsutani S; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Hirakawa K; Ohira M
Cancer Sci; 2018 Apr; 109(4):966-979. PubMed ID: 29464828
[TBL] [Abstract][Full Text] [Related]
17. A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8
Jeon SH; Lim YJ; Koh J; Chang WI; Kim S; Kim K; Chie EK
Radiother Oncol; 2021 Sep; 162():124-131. PubMed ID: 34265357
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
[TBL] [Abstract][Full Text] [Related]
19. Local environment in biopsy better predict the pathological response to neoadjuvant chemoradiotherapy in rectal cancer.
Huang Y; Lou XY; Zhu YX; Wang YC; Zhang L; Liu HL; Wang C; Zhan HM; Cheng ZQ; Tan WY; Wang L; Fan XJ
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30867256
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
